Journals / Genel Tıp Dergisi / 2019 / Cilt: 29 - Sayı: 3

Akciğerin sarkomatoid karsinomlarının klinik ve radyometabolik özellikleri

Pages
113–118
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Radiometabolic characteristics of sarcomatoid carcinomas are associated with survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the clinical and radiometabolic (PET-CT) characteristics of lung sarcomatoid carcinomas (SC) and to investigate the effect on survival.
📊
Key Findings & Data:Material and Methods: Patients diagnosed with lung cancer between January 2014 and December 2016 were retrospectively analyzed.
💡
Conclusion & Impact:Radiometabolic characteristics of sarcomatoid carcinomas are associated with survival.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the clinical and radiometabolic (PET-CT) characteristics of lung sarcomatoid carcinomas (SC) and to investigate the effect on survival. Material and Methods: Patients diagnosed with lung cancer between January 2014 and December 2016 were retrospectively analyzed. Clinical and radiometabolic characteristics of non-small cell lung carcinoma and sarcomatoid cancer were compared with each other. All data was analyzed by Chi square, Mann Whitney U, Kaplan-Meier Logrank method. In all tests p <0.05 was considered significant. Results: A total of 275 cases were studied, 256 of them (93%) were NSCLC and 19 of them were SC (7%). Clinical-radiological and demographic findings of the two groups were not statistically different. When the cancer stages were examined, the number of stage 4 cases in the NSCLC group was 105 (41%) whereas it was 14 (68.4%) in the SC group ( p=0.02). When the PET-CT SUVmax values of the cases were examined, the mean SUVmax value in the NSCLC group was 16.9 ± 9.2, whereas it was 20.8 ± 10.4 in the SK group (p = 0.047). Metabolic size measured in PET-CT were 51.1 ± 24.5 mm in the NSCLC group and 72.1 ± 32.7 mm in the SC group (p = 0.003). The median survival in the NSCLC group was 18.1 ± 1 months and 6.9 ± 1.1 months in the SC group (p = 0.003). Conclusion: Radiometabolic features of sarcomatoid carcinomas are different from NSCLC. Radiometabolic characteristics of sarcomatoid carcinomas are associated with survival.

Özet

Amaç: Akciğerin sarkomatoid karsinomlarının (SK) klinik ve radyometabolik (PET-BT) özelliklerinin incelenmesi ve bu özelliklerin sağ kalım üzerine etkisini araştırmak. Gereç ve Yöntem: Ocak 2014-Aralık 2016 arasında akciğer kanseri tanısı alan olguların kayıtları retrospektif olarak incelendi. Küçük hücreli dışı akciğer kanseri (KHDAK) ve SK tanısı alan olguların dosyaları ayrıldı. Bu olguların klinik ve radyometabolik özellikleri birbirleri ile karşılaştırıldı. Gruplara ait veriler Ki Kare, Mann Whitney U ile karşılaştırıldı. Sağ kalım analizleri Kaplan-Meier, Logrank yöntemi ile hesaplandı. Tüm testlerde p<0.05 anlamlı olarak kabul edildi. Bulgular: Çalışmaya 256’sı (%93) KHDAK, 19’u (%7) SK olmak üzere toplam 275 olgu alındı. İki grubun klinik-radyolojik ve demografik bulguları arasında fark yoktu. Kanser evreleri incelendiğinde KHDAK grubunda evre 4 olgu sayısı 105 (%41) iken SK grubunda 14 (%68.4) idi (p=0.02). Olguların PET-BT SUVmax değerleri incelendiğinde KHDAK grubunda ortalama SUVmax değeri 16.9±9.2 iken SK grubunda 20.8±10.4 idi (p=0.047). Olguların PET-BT’de ölçülen metabolik boyutlar incelendiğinde KHDAK grubunda 51.1±24.5 mm, SK grubunda 72.1±32.7 mm idi (p=0.003). KHDAK grubunda ortanca genel sağ kalım 18.1±1 ay iken SK grubunda 6.9±1.1 ay idi (p=0.003). Sonuç: Akciğerin SK’leri radyometabolik özellikleri diğer KHDAK’lerden farklıdır. SK’lerin radyometabolik özellikleri sağ kalım ile ilişkilidir.

🔖

Cite This Article

DOĞAN, C., KIRAL, N., PARMAKSIZ, E. T., SAĞMEN, S. B., FİDAN, A., SALEPÇİ, B., CÖMERT, S. Ş. (2019). Akciğerin sarkomatoid karsinomlarının klinik ve radyometabolik özellikleri. Genel Tıp Dergisi, Cilt: 29 - Sayı: 3, 113–118. https://ajindex.com/articles/160434

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Travis WD, Brambilla E, Nicholson AG, et al. WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015; 10: 1243-60.
  2. Kefeli M, Yıldız L, Oğuz A, Uzun O, Kandemir B. Akciğerin sarkomatoid karsinomları: Üç olgu sunumu. Türk Patoloji Dergisi 2008; 24: 64-8.
  3. Uğurluer G, Atalar B, İkizler HAS ve ark. Serviks Kanserli Hastalarda PET/BT Tetkikinde Primer Tümörün FDG Tutulum Derecesi ile Lenf Nodu Metastazı Arasındaki İlişki. ACU Sağlık Bil Derg 2016; 3: 129-33. Sönmezoğlu K. Akciğer kanserlerinde FDG-PET uygulamaları. Tüberküloz ve Toraks Dergisi 2005; 53: 94-112.
  4. Cox BL, Mackie TR, Eliceiri KW. The sweet spot: FDG and other 2-carbon glucose analogs for multi-modal metabolic imaging of tumor metabolism.Am J Nucl Med Mol Imaging 2014; 5: 1-13.
  5. Rapicetta C, Lococo F, Stefani A, et al. Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic ((18)F-FDG PET/ CT) Findings and Correlation with Clinico-Pathological and Survival Results. Lung 2016; 194: 653-7.
  6. Zhang Y, Li B, Shi H, Cai L, Gu Y. Sarcomatoid carcinoma of the lung mimics aspergilloma on ¹⁸F-FDG PET/CT. Hell J Nucl Med 2015; 18: 268-70.
  7. Nakajima M, Kasai T, Hashimoto H, Iwata Y, Manabe H. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 1999; 86: 608-16.
  8. Shen XY, Lin ZF, Lin Q, et al. Pulmonary sarcomatoid carcinoma: a case report. Contemp Oncol (Pozn) 2013; 17: 210–3.
  9. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 2013; 8: 1574-7.
  10. Giroux Leprieur E, Lavole A, Ruppert A-M, et al. Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology 2012; 17: 134-42.
  11. Vieira T, Girard N, Ung M, et al. Efficacy of firstline chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 2013; 8: 1574–7.
  12. Roesel C, Terjung S, Weinreich G, et al. Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. Interact Cardiovasc Thorac Surg 2017; 24: 407-13.
  13. Martin LW, Correa AM, Ordonez NG, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg 2007; 84: 973-80.
  14. Steuer CE, Behera M, Liu Y, et al. Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. Clin Lung Cancer 2017; 18: